Abstract:Serotonin (5-HT) receptors are proteins involved in various neurological and biological processes, such as aggression, anxiety, appetite, cognition, learning, memory, mood, sleep, and thermoregulation. They are commonly associated with drug abuse and addiction due to their importance as targets for various pharmaceutical and recreational drugs. However, due to a high sequence similarity/identity among 5-HT receptors and the unavailability of the 3D structure of the different 5-HT receptor, no report was available so far regarding the systematical comparison of the key and selective residues involved in the binding pocket, making it difficult to design subtype-selective serotonergic drugs. In this work, we first built and validated three-dimensional models for all 5-HT receptors based on the existing crystal structures of 5-HT1B, 5-HT2B, and 5-HT2C. Then, we performed molecular docking studies between 5-HT receptors agonists/inhibitors and our 3D models. The results from docking were consistent with the known binding affinities of each model. Sequentially, we compared the binding pose and selective residues among 5-HT receptors. Our results showed that the affinity variation could be potentially attributed to the selective residues located in the binding pockets. Moreover, we performed MD simulations for 12 5-HT receptors complexed with ligands; the results were consistent with our docking results and the reported data. Finally, we carried out off-target prediction and blood-brain barrier (BBB) prediction for Captagon using our established hallucinogen-related chemogenomics knowledgebase and in-house computational tools, with the hope to provide more information regarding the use of Captagon. We showed that 5-HT2C, 5-HT5A, and 5-HT7 were the most promising targets for Captagon before metabolism. Overall, our findings can provide insights into future drug discovery and design of medications with high specificity to the individual 5-HT receptor to decrease the risk of addiction and prevent drug abuse.

A Computational Perspective on Drug Discovery and Signal Transduction Mechanism of Dopamine and Serotonin Receptors in the Treatment of Schizophrenia

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Trends in Application of Advancing Computational Approaches in GPCR Ligand Discovery.

Computer-Aided Drug Design towards New Psychotropic and Neurological Drugs

Dopaminergic Pharmacology Revealed by Structures of Human Dopamine D3 Receptor-G I Complexes

Structural insight into the serotonin (5-HT) receptor family by molecular docking, molecular dynamics simulation and systems pharmacology analysis

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

A Bioinformatics Approach to Potential Therapeutic Applications in Schizophrenia

The Use of Computational Approaches in the Discovery and Mechanism Study of Opioid Analgesics

Structural insights into the human D1 and D2 dopamine receptor signaling complexes

Structure, function and drug discovery of GPCR signaling

Structural genomics of the human dopamine receptor system

Molecular insights into orphan G protein‐coupled receptors relevant to schizophrenia

Recent Advances Towards the Discovery of Dopamine Receptor Ligands

G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery

Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors

G Protein-Coupled Receptors in Neurodegenerative Diseases and Psychiatric Disorders

Discovery of GPCR ligands for probing signal transduction pathways

Recent Trends and Applications of Molecular Modeling in GPCR–Ligand Recognition and Structure-Based Drug Design

Structure-based drug design for dopamine D3 receptor.

Computational modeling of structure-function of g protein-coupled receptors with applications for drug design.